HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.

Abstract
Recently, it has been proposed that activation of either metabotropic glutamate receptors e.g. mGlu(5) by positive allosteric modulators or stimulation of mGluR(2/3) receptors by agonists may offer new strategy in schizophrenia treatment. The aim of the present study was to compare the effect of mGlu(5) receptor positive allosteric modulator, ADX47273 (S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone), mGluR(2/3) agonist, LY354740 ((1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate) and selected neuroleptics in animal models for positive schizophrenia symptoms. ADX47273 (3 and 10mg/kgi.p.), the typical antipsychotic haloperidol (0.1 and 0.2mg/kgi.p.), the atypical antipsychotics aripiprazole (1.25-5mg/kgi.p.) and olanzapine (2.5 and 5mg/kgi.p.) all reduced amphetamine-induced hyperlocomotion in Sprague-Dawley rats, unlike the mGlu(2/3) receptor agonist LY354740 (1-10mg/kgi.p.). Interestingly, haloperidol (0.1 and 0.2mg/kgi.p.), aripiprazole (1.25-5mg/kgi.p.) and olanzapine (1.25-5mg/kgi.p.), but not ADX47273 (1-10mg/kgi.p.), all reduced spontaneous locomotion and rearings at doses effective against amphetamine-induced hyperlocomotion. This indicates that the effect of ADX47273 in combination with amphetamine may be specific, and also suggests a lack of sedative side effects. Moreover, ADX47273 (30mg/kgi.p.), haloperidol (0.1 and 0.2mg/kgi.p.) and aripiprazole (5 and 10mg/kgi.p.) reversed apomorphine (0.5mg/kgs.c.)-induced deficits of prepulse inhibition, whereas neither LY354740 (1-10mg/kgi.p.) nor olanzapine (1.25-5mg/kgi.p.) produced this effect. Lack of effect of olanzapine was unexpected and at present no convincing explanation can be provided. In conclusion, in selected rodent models for positive schizophrenia symptoms, ADX47273 showed better efficacy than LY354740.
AuthorsChantal Schlumberger, Małgorzata Pietraszek, Andreas Gravius, Kai-Uwe Klein, Sergio Greco, Lorenzo Morè, Wojciech Danysz
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 623 Issue 1-3 Pg. 73-83 (Nov 25 2009) ISSN: 1879-0712 [Electronic] Netherlands
PMID19765575 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antipsychotic Agents
  • Bridged Bicyclo Compounds
  • Dopamine Agents
  • Excitatory Amino Acid Agents
  • Excitatory Amino Acid Agonists
  • Oxadiazoles
  • Piperidines
  • Receptor, Metabotropic Glutamate 5
  • Receptors, Metabotropic Glutamate
  • S-(4-fluorophenyl)-(3-(3-(4-fluorophenyl)-(1,2,4)-oxadiazol-5-yl)piperidin-1-yl)methanone
  • eglumetad
Topics
  • Allosteric Regulation
  • Animals
  • Antipsychotic Agents (pharmacology, therapeutic use)
  • Behavior, Animal (drug effects)
  • Bridged Bicyclo Compounds (therapeutic use)
  • Dopamine Agents (pharmacology)
  • Dose-Response Relationship, Drug
  • Excitatory Amino Acid Agents (pharmacokinetics, therapeutic use)
  • Excitatory Amino Acid Agonists (therapeutic use)
  • Male
  • Motor Activity (drug effects)
  • Neural Inhibition (drug effects)
  • Oxadiazoles (pharmacokinetics, therapeutic use)
  • Piperidines (pharmacokinetics, therapeutic use)
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Metabotropic Glutamate 5
  • Receptors, Metabotropic Glutamate (agonists, metabolism)
  • Reflex, Startle (drug effects)
  • Schizophrenia (chemically induced, drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: